MeiraGTx
Biotechnology Research • 
92 Brittania Walk, London/New York, United Kingdom • 201-500 Employees
Company overview
| Headquarters | 92 Brittania Walk, London/New York, N17NQ, GB |
| Phone number | +446464902965 |
| Website | |
| SIC | 283 |
| Keywords | Life Sciences, Biotech, Gene Therapy, Neurodegenerative Disease, Rare Disease, Inherited Retinopathies |
| Founded | 2015 |
| Employees | 201-500 |
| Socials |
Key Contacts at MeiraGTx
Robby Dupuy
Director Of Engineering At Meiragtx
Adeyemi Afuwape
Director, Cmc Lead, Regulatory Affairs
Greg Simmonds
Senior Director Of Global Technical Operations
Michael Howell
Site Operations Director
Jack Mccarthy
Director Of Supply Chain Planning & Product Supply
Girish Chitnis
Senior Director Device Engineering
James Norton
Director Of Analytical Development
Antony Stanley
Quality Director Head Of Quality Shannon
Francois-Xavier Toubhantz
Director Of Technical Services
Victor Sanchez Tarre
Director, Data Science
MeiraGTx Email Formats
MeiraGTx uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@meiragtx.com), used 64.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@meiragtx.com | 64.1% |
{first initial}.{last name} | j.doe@meiragtx.com | 33.9% |
About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on delivery of metabolic peptides including GLP-1, GIP, Glucagon and PYY using oral small molecules, as well as cell therapy for oncology and autoimmune diseases. Although initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx has developed the technology to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains great.
MeiraGTx revenue & valuation
| Annual revenue | $38,000,000 |
| Revenue per employee | $98,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $121,400,000 |
| Total funding | $80,000,000 |
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
MeiraGTx has 207 employees across 14 departments.
Departments
Number of employees
Funding Data
Explore MeiraGTx's funding history, including investment rounds, total capital raised, and key backers.
MeiraGTx Tech Stack
Discover the technologies and tools that power MeiraGTx's digital infrastructure, from frameworks to analytics platforms.
CDN
JavaScript libraries
Video players
JavaScript libraries
Font scripts
JavaScript libraries
Webmail
Programming languages
Blogs
Analytics
UI frameworks
SEO
United Arab Emirates
IndiaFrequently asked questions
4.8
40,000 users
